NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDSelpercatinib Retsevmo®
(40mg, 80mg hard capsules) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Selpercatinib Selpercatinib [Specialist Drug] Malignant Disease, Targeted Therapy Responsive Malignancy, Antineoplastic Drugs Protein Kinase Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA1038: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over
NICE TA1039: Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over
NICE TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer